Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Clover Health Investments Corp’s stock clocked out at $2.75, up 2.23% from its previous closing price of $2.69. In other words, the price has increased by $2.23 from its previous closing price. On the day, 4.05 million shares were traded. CLOV stock price reached its highest trading level at $2.8 during the session, while it also had its lowest trading level at $2.6949.
Ratios:
To gain a deeper understanding of CLOV’s stock, we examine its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on December 17, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On October 07, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $4. Cowen Upgraded its Underperform to Market Perform on February 02, 2022, whereas the target price for the stock was revised from $7 to $3.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 13 ’25 when Loengard Anna U bought 26,500 shares for $2.59 per share. The transaction valued at 68,755 led to the insider holds 29,610 shares of the business.
Garipalli Vivek bought 415,000 shares of CLOV for $929,600 on Aug 07 ’25. The Director now owns 1,824,267 shares after completing the transaction at $2.24 per share. On Aug 08 ’25, another insider, Garipalli Vivek, who serves as the Director of the company, bought 31,980 shares for $2.17 each. As a result, the insider paid 69,397 and bolstered with 1,856,247 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 1409410688 and an Enterprise Value of 1208137472. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.88 while its Price-to-Book (P/B) ratio in mrq is 3.86. Its current Enterprise Value per Revenue stands at 0.751 whereas that against EBITDA is -29.423.
Stock Price History:
The Beta on a monthly basis for CLOV is 2.09, which has changed by 0.09561753 over the last 52 weeks, in comparison to a change of 0.18469036 over the same period for the S&P500. Over the past 52 weeks, CLOV has reached a high of $4.87, while it has fallen to a 52-week low of $2.12. The 50-Day Moving Average of the stock is -0.95%, while the 200-Day Moving Average is calculated to be -18.72%.
Shares Statistics:
It appears that CLOV traded 9.00M shares on average per day over the past three months and 3896620 shares per day over the past ten days. A total of 390.25M shares are outstanding, with a floating share count of 385.35M. Insiders hold about 24.81% of the company’s shares, while institutions hold 28.67% stake in the company. Shares short for CLOV as of 1755216000 were 50279320 with a Short Ratio of 5.59, compared to 1752537600 on 36198932. Therefore, it implies a Short% of Shares Outstanding of 50279320 and a Short% of Float of 12.3.
Earnings Estimates
Investors are keenly observing as 1.0 analysts analyze and rate the current performance of Clover Health Investments Corp (CLOV) in the stock market.The consensus estimate for the next quarter is $0.0, with high estimates of $0.0 and low estimates of $0.0.
Analysts are recommending an EPS of between $0.1 and $0.1 for the fiscal current year, implying an average EPS of $0.1. EPS for the following year is $0.19, with 1.0 analysts recommending between $0.19 and $0.19.
Revenue Estimates
In the current quarter, 4 analysts expect revenue to total $467.18M. It ranges from a high estimate of $475.4M to a low estimate of $455.43M. As of the current estimate, Clover Health Investments Corp’s year-ago sales were $330.99MFor the next quarter, 4 analysts are estimating revenue of $472.87M. There is a high estimate of $486.6M for the next quarter, whereas the lowest estimate is $460.75M.
A total of 4 analysts have provided revenue estimates for CLOV’s current fiscal year. The highest revenue estimate was $1.9B, while the lowest revenue estimate was $1.86B, resulting in an average revenue estimate of $1.88B. In the same quarter a year ago, actual revenue was $1.37BBased on 4 analysts’ estimates, the company’s revenue will be $2.39B in the next fiscal year. The high estimate is $2.6B and the low estimate is $2.25B.
